Contemporary OB/GYN week in review: vulvovaginal candidiasis, monoclonal antibodies, and more

Contemporary OB/GYN week in review: vulvovaginal candidiasis, monoclonal antibodies, and more

Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, January 29 - Friday, February 2, 2024), and click each link to read and watch anything you may have missed.

1.) Oteseconazole outperforms fluconazole in treating severe vulvovaginal candidiasis

Oteseconazole outperforms fluconazole in treating severe vulvovaginal candidiasis | Image Credit: © Egor - © Egor - stock.adobe.com.

A phase 3 trial demonstrated that oteseconazole (VIVJOA; Mycovia Pharmaceuticals) capsules exhibit improved therapeutic and mycological cure rates to fluconazole for treating severe vulvovaginal candidiasis.

Click here for the full article.

2.) How monoclonal antibodies revolutionize sexual health

How monoclonal antibodies revolutionize sexual health | Image Credit: © StratfordProductions - © StratfordProductions - stock.adobe.com.

Explore the potential of monoclonal antibodies for contraception and sexually transmitted infection prevention, providing a comprehensive review of their safety, efficacy, and pharmacokinetics.

Click here for the full article.

3.) Two-dose HPV vaccination postpartum shows efficacy

Two-dose HPV vaccination postpartum shows efficacy | Image Credit: © Tobias Arhelger - © Tobias Arhelger - stock.adobe.com.

A recent study revealed a 2-dose regimen of human papillomavirus vaccination in postpartum individuals is as effective as a 3-dose approach, providing valuable insights into optimizing vaccination strategies against the virus.

Click here for the full article.

4.) The Guardians app shows efficacy for reducing perinatal depression

The Guardians app shows efficacy for reducing perinatal depression | Image Credit: © InsideCreativeHouse - © InsideCreativeHouse - stock.adobe.com.

Preliminary findings suggest The Guardians mobile app, blending gaming and behavioral activation techniques, could be a solution for alleviating perinatal depression among pregnant women.

Click here for the full article.

5.) Dexmedetomidine found effective for reducing postpartum depression risk

Dexmedetomidine found effective for reducing postpartum depression risk | Image Credit: © LUMEZIA.com - © LUMEZIA.com - stock.adobe.com.

A recent study revealed that early postpartum administration of dexmedetomidine significantly reduces the risk of postpartum depression among women with prenatal depression.

Click here for the full article.